Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Trends in Endocrinology & Metabolism, ISSN: 1043-2760, Vol: 32, Issue: 7, Page: 500-514
2021
- 121Citations
- 123Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations121
- Citation Indexes121
- 121
- CrossRef52
- Captures123
- Readers123
- 123
- Mentions2
- News Mentions2
- 2
Most Recent News
Serum Lactate Dehydrogenase Is a Novel Predictor for the Severity in the Patients With MAFLD: A Cross-Sectional Study in Hefei, China
Introduction As one of the metabolic disorders, metabolism-associated fatty liver disease (MAFLD) affects the majority of obese patients and is associated with a range of
Review Description
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition characterized by hepatic fat accumulation combined with underlying metabolic dysregulation. Having evolved from the previous term of nonalcoholic fatty liver disease (NAFLD), the term MAFLD more closely implicates the presence of overweight/obesity, type 2 diabetes, or metabolic dysregulation as essential pathogenic factors, leading to better identification of individuals with this metabolic liver disease. Low-grade inflammation, increased oxidative stress, mitochondrial dysfunction, and intestinal dysbiosis are also involved in its pathogenesis. MAFLD is not only associated with liver-related complications, but also with adverse cardiometabolic outcomes. Further studies are needed to assess whether the newly proposed definition of MAFLD is more accurate than the NAFLD in predicting the adverse liver-related and extrahepatic outcomes.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1043276021000898; http://dx.doi.org/10.1016/j.tem.2021.04.008; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85105510476&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33975804; https://linkinghub.elsevier.com/retrieve/pii/S1043276021000898; https://dx.doi.org/10.1016/j.tem.2021.04.008
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know